Treatment with investigational oral therapy BIIB122/DNL151 safely lowered the activity of disease biomarkers that reflect LRRK2 activity, a protein whose mutations are associated with Parkinson’s disease, according to results from two Phase 1 clinical studies.
Oral BIIB122/DNL151 Safely Lowers LRRK2 A... - Cure Parkinson's
Oral BIIB122/DNL151 Safely Lowers LRRK2 Activity in Phase 1 Trials
Written by
Kia17
To view profiles and participate in discussions please or .
5 Replies
•
They are off to a good start. Look forward to a future phase 2 trial with data on disease modifying effect.
Actual press release from Denali here:
Definitely one to watch
Thanks for posting! Very encouraging!
Hopefully this is a cure, pray 🙏🙏🙏 thanks for sharing!
Not what you're looking for?
You may also like...
Phase 3, the Lighthouse study, Biogen and Denali, LRRK2 inhibitor BIIB122; New clinical trial registered
New clinical trial registered: Biogen and Denaliti have initiated the 2nd late-stage study of...
Phase 4 study to evaluate efficacy of orally administrated Trehalose in individuals with idiopathic & LRRK2-associated Parkinsons
New clinical trial registered:
NeuromedIRCCS researchers have registered a small (N=20) open...
Oral ANVS401 Improves Patients’ Motor Skills in Phase 2 Trial
'
Once-a-day treatment with oral ANVS401 was found to significantly improve motor skills among...
Clinical Trial Highlights – an update on previously reviewed trials (Phase 3 in focus)
https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd229001...
Am I Taking the Wrong Vitamin B12? Adenosylcobalamin (AdoCbl) vs Methylcobalamin (MeCbl)
Thanks to @[222784] for sharing a link to this document: Vitamin B12 modulates Parkinson’s disease...
B12 Adenosylcobalamin form inhibits LRRK2
Protective role of ibuprofen.
Stem Cells Trials
Potential Parkinson’s Treatment, CDNF, Shows Safety and Tolerability at One Year
